Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

A Phase 1b/2 Study of AST-008 Combined With Pembrolizumab in Patients With Advanced Solid Tumors

Next Previous
Trial Profile

A Phase 1b/2 Study of AST-008 Combined With Pembrolizumab in Patients With Advanced Solid Tumors

Status: Recruiting
Phase of Trial: Phase I/II

Latest Information Update: 07 Nov 2019

Price : $35 *
  • Adis is an information provider.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
  • A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

  • Drugs AST 008 (Primary) ; Pembrolizumab (Primary)
  • Indications Head and neck cancer; Malignant melanoma; Merkel cell carcinoma; Skin cancer; Solid tumours; Squamous cell cancer
  • Focus Adverse reactions
  • Sponsors Exicure

    • Most Recent Events

    • 07 Nov 2019 According to the Exicure media release, the preliminary results from phase Ib is expected in december 2019.
    • 07 Nov 2019 According to the Exicure media release, as of 1 November 2019, 13 patients in the first four cohorts of the phase Ib stage have been dosed.
    • 12 Aug 2019 Planned number of patients changed from 81 to 130.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Legal

Back to top